<DOC>
	<DOCNO>NCT01460940</DOCNO>
	<brief_summary>This phase II trial study well give panobinostat together lenalidomide work treat patient relapsed refractory Hodgkin lymphoma . Panobinostat may stop growth cancer cell block enzymes need cell growth . Biological therapy , lenalidomide , may stimulate immune system different way stop cancer cell grow . Giving panobinostat together lenalidomide may effective treatment Hodgkin lymphoma</brief_summary>
	<brief_title>A Phase II Trial Panobinostat Lenalidomide Patients With Relapsed Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine overall response rate ( ORR ) , include complete response ( CR ) partial response ( PR ) , combine lenalidomide panobinostat patient relapse refractory Hodgkin 's lymphoma . SECONDARY OBJECTIVES : I. Assess safety tolerability combine lenalidomide panobinostat patient previously treat Hodgkin 's lymphoma . II . Determine progression-free survival ( PFS ) patient previously treat Hodgkin 's lymphoma receiving combine lenalidomide panobinostat . III . Evaluate change natural killer ( NK ) cell number function , plasma cytokine , gene expression profile peripheral blood , plasma protein via proteomics , , , lenalidomide panobinostat therapy . IV . Determine level histone acetylation treatment panobinostat . V. Determine pharmacokinetics lenalidomide presence panobinostat . VI . To collect deoxyribonucleic acid ( DNA ) sample potential later analysis association outcomes polymorphisms gene cod drug metabolize enzyme , transporter molecular target lenalidomide panobinostat . OUTLINE : Patients receive panobinostat orally ( PO ) day 1 , 3 , 5 week 1-4 lenalidomide PO day 1-7 week 1-3 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow least every 3 month 2 year , every 6 month 3-5 year</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Histologically confirm classical lymphocyte predominant Hodgkin 's lymphoma relapse refractory least one prior chemotherapy ; patient Hodgkin 's lymphoma may one follow World Health Organization ( WHO ) subtypes : Nodular sclerosis Hodgkin 's lymphoma Mixed cellularity Hodgkin 's lymphoma Lymphocyterich Hodgkin 's lymphoma Lymphocytedeplete Hodgkin 's lymphoma Nodular Lymphocytepredominant Hodgkin 's lymphoma Patients must relapse progress least one prior cytotoxic chemotherapy Previous autologous allogeneic stem cell transplantation permit Previous treatment either single agent panobinostat lenalidomide permit Absolute neutrophil count ( ANC ) &gt; = 1200/μL Platelets &gt; = 100,000/μl Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x upper limit normal ( ULN ) Serum bilirubin = &lt; 1.5 x ULN Calculated creatinine clearance &gt; = 60ml/min CockcroftGault estimation CrCI Measurable Disease must present either physical examination image study ; nonmeasurable disease alone acceptable ; tumor mass &gt; 1 cm acceptable ; lesion consider nonmeasurable include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Bone marrow involvement ( involvement nonHodgkin lymphoma note ) Baseline multi gate acquisition ( MUGA ) echocardiogram ( ECHO ) must demonstrate leave ventricular ejection fraction ( LVEF ) &gt; = 45 % Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Able provide write informed consent obtain prior participation study relate procedure perform Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day within 24 hour prior start Cycle 1 lenalidomide ( prescription must fill within 7 day require RevAssist ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant aspirin increase risk venous thrombosis may use warfarin low molecular weight heparin ) Patients candidate high dose chemotherapy autologous stem cell transplantation curative intent enrol Patients active central nervous system ( CNS ) lymphoma Use valproic acid medical condition receive protocol treatment within 5 day prior first panobinostat dose Impaired cardiac function clinically significant cardiac disease , include one following : History presence sustain ventricular tachyarrhythmia ; ( patient history atrial arrhythmia eligible discuss Novartis prior enrollment ) Any history ventricular fibrillation Torsade de Pointes Bradycardia define heart rate ( HR ) &lt; 50 beat per minute ( bpm ) ; patient pacemaker eligible HR &gt; = 50 bpm Screening electrocardiogram ( ECG ) QTc &gt; 450 msec Right bundle branch block + leave anterior hemiblock ( bifascicular block ) Patients myocardial infarction unstable angina = &lt; 6 month prior start study drug Other clinically significant heart disease ( e.g. , congestive heart failure [ CHF ] New York [ NY ] Heart Association class III IV , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption panobinostat Patients diarrhea &gt; Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes active uncontrolled infection ) include abnormal laboratory value , could cause unacceptable safety risk compromise compliance protocol Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug Known hypersensitivity thalidomide lenalidomide . The development erythema nodosum characterize desquamate rash take thalidomide similar drug Pregnant breastfeeding female Patients know positivity human immunodeficiency virus ( HIV ) hepatitis B C ; baseline test HIV hepatitis C require . Patients seropositive hepatitis B virus vaccine eligible . Concurrent use anticancer agent treatments Patients significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>refractory Hodgkin 's lymphoma</keyword>
	<keyword>panobinostat</keyword>
	<keyword>lenalidomide</keyword>
</DOC>